Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 17/20 | 0.72 |
| ▸ | ECE1 | P42892 | 1/20 | 0.71 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.71 |
| ▸ | CCKBR | P32239 | 1/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350003 | 0.95 | GLP1R (0.78) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29546813 | 0.91 | GLP1R (0.75) | GLP1RECE1MUS81CCKBR | |
| SCHEMBL30683162 | 0.90 | GLP1R (0.81) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29360422 | 0.89 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29370432 | 0.89 | GLP1R (0.84) | GLP1R | |
| SCHEMBL31578362 | 0.89 | GLP1R (0.73) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL31060658 | 0.89 | GLP1R (0.89) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Glp-1 SCHEMBL29353361 | 0.89 | GLP1R (0.89) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL31104924 | 0.88 | GLP1R (0.66) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29395456 | 0.88 | GLP1R (0.78) | GLP1RECE1MUS81CCKBRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236656-A1 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | Amide Technologies (US) | 2025-07-24 | — | — | US | claimed |
| EP-4582441-A2 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | Amide Technologies (US) | 2025-07-09 | — | — | EP | claimed |
| US-20250122239-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2025-04-17 | — | — | US | claimed |
| CN-119775356-A | Preparation method of GLP-1 or analogue thereof | 汉肽生物医药集团有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-20240261421-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS | AMGEN INC. (US) | 2024-08-08 | — | — | US | claimed |
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| US-20230183309-A1 | STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2023-06-15 | — | — | US | claimed |
| EP-4077366-A1 | STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| US-20220056077-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | RATNER, Cecilia (DK) | 2022-02-24 | — | — | US | claimed |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | TERRESTRIAL BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122081402-A | Method for preparing semaglutin by using circRNA and related composition | — | 2026-05-26 | — | — | CN | disclosed |
| US-12630600-B2 | GLP-1 and glucagon dual agonist peptides with improved biological stability | MEDIMMUNE LIMITED (GB) | 2026-05-19 | — | — | US | disclosed |
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026098581-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | 深圳奥礼生物科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-114126639-A | Pharmaceutical compositions of glucagon and GLP-1 co-agonist peptides | 免疫医疗有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220056077-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | RATNER, Cecilia (DK) | 2022-02-24 | — | — | US | disclosed |
| US-11248037-B2 | Multivalent heteromultimer scaffold design and constructs | ZYMEWORKS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| EP-3946261-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220033457-A1 | TREATMENT OF NEUROLOGICAL DISEASES | UNIVERSITY OF LANCASTER (GB) | 2022-02-03 | — | — | US | disclosed |
| US-11230584-B2 | Glucagon/GLP-1 agonists for the treatment of obesity | MEDIMMUNE LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183309-A1 | STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF | GLP1R, IAPP, GPR119 | GLP1R 1/4885ECE1 2947/4885MUS81 3965/4885 |
| US-12630600-B2 | GLP-1 and glucagon dual agonist peptides with improved biological stability | GLP1R, GIPR, GCGR | GLP1R 1/4885ECE1 373/4885MUS81 4365/4885 |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | GLP1R, NPY1R, NPY4R | GLP1R 1/4885ECE1 4125/4885MUS81 4876/4885 |
| US-20250236656-A1 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | GIPR, GRPR, SCTR | GLP1R 5/4885ECE1 894/4885MUS81 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.